Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2022-09-19 00:00:00 ET · period of report 2022-09-15 · accession 0001140361-22-033878 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-09-19 | 2022-09-15 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +50.0K | 53.9K | +1,275% | $0 |
| D | 2022-09-19 | 2022-09-15 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +68.9K | 68.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-09-15 | A | A | 50,000 | $0.00 | 53,923 | D | — | — | (F1) Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-09-15 | A | A | 68,897 | $0.00 | 68,897 | D | $3.50 · — to 2032-09-14 | 68,897 Common Shares | (F2) Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date. |